SGE Consulting will have the opportunity to participate in the presentation of 2 posters during Virtual ISPOR Europe 2020, 16-19 November 2020. These publications concern the Impella 5.0® and Impella CP® technologies of the Abiomed company.
Impella 5.0®, a short term mechanical circulatory support device (MCS), has been recently approved by HAS (CNEDiMTS advice, 24 March 2020) in adult patients suffering from left-ventricular dysfunction (LVD) in refractory post-cardiogenic shock. The budget impact associated with the introduction of Impella 5.0® has been estimated from the French payer perspective and accepted at ISPOR.
The budget impact associated with the introduction of Impella CP® a short term mechanical circulatory support device (MCS), in adult patients under 75 in post-refractory cardiogenic shock after an acute myocardial infarction (AMI) has been estimated from the French payer perspective and accepted at ISPOR.